Invesco Ltd. boosted its holdings in shares of The Chemours Company (NYSE:CC - Free Report) by 141.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,020,001 shares of the specialty chemicals company's stock after acquiring an additional 597,638 shares during the period. Invesco Ltd. owned 0.68% of Chemours worth $17,238,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of CC. Norges Bank acquired a new position in shares of Chemours during the 4th quarter worth approximately $30,702,000. Bank of Montreal Can lifted its position in Chemours by 1,496.4% during the fourth quarter. Bank of Montreal Can now owns 953,240 shares of the specialty chemicals company's stock worth $16,110,000 after buying an additional 893,530 shares in the last quarter. Peregrine Capital Management LLC acquired a new position in Chemours during the fourth quarter worth $5,731,000. Channing Capital Management LLC purchased a new stake in Chemours in the 4th quarter valued at $4,701,000. Finally, Schroder Investment Management Group acquired a new stake in shares of Chemours in the 4th quarter worth $4,393,000. Institutional investors and hedge funds own 76.26% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on CC. Barclays lowered their price target on shares of Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 1st. Mizuho set a $15.00 target price on shares of Chemours in a report on Tuesday, April 15th. The Goldman Sachs Group cut their price target on shares of Chemours from $24.00 to $21.00 and set a "neutral" rating for the company in a report on Tuesday, January 7th. BMO Capital Markets decreased their price objective on Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a report on Wednesday, February 19th. Finally, Truist Financial cut their target price on Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $21.56.
Read Our Latest Report on Chemours
Chemours Trading Down 1.6 %
NYSE CC traded down $0.21 on Friday, reaching $12.24. The stock had a trading volume of 368,092 shares, compared to its average volume of 1,855,357. The Chemours Company has a 12-month low of $9.33 and a 12-month high of $29.21. The stock has a fifty day moving average price of $13.41 and a two-hundred day moving average price of $17.12. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of 21.43 and a beta of 1.84. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70.
Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.01. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The firm had revenue of $1.36 billion for the quarter, compared to analyst estimates of $1.37 billion. As a group, sell-side analysts forecast that The Chemours Company will post 2.03 EPS for the current fiscal year.
Chemours Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were paid a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 8.17%. The ex-dividend date of this dividend was Friday, February 28th. Chemours's payout ratio is 175.44%.
Chemours Company Profile
(
Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Further Reading

Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.